Journal
BIOMOLECULES
Volume 11, Issue 12, Pages -Publisher
MDPI
DOI: 10.3390/biom11121911
Keywords
KDM; Jumonji C (JmjC) domain; histone demethylation; leukemia; myelodysplastic syndrome; myeloproliferative neoplasm; targeted therapy
Categories
Ask authors/readers for more resources
Histone demethylases, particularly Jumonji C (JmjC) domain-containing proteins, play critical roles in myeloid malignancies and may serve as potential targets for drug interventions. However, understanding the context-dependent mechanisms of these proteins presents challenges that require further exploration.
Histone methylation tightly regulates chromatin accessibility, transcription, proliferation, and cell differentiation, and its perturbation contributes to oncogenic reprogramming of cells. In particular, many myeloid malignancies show evidence of epigenetic dysregulation. Jumonji C (JmjC) domain-containing proteins comprise a large and diverse group of histone demethylases (KDMs), which remove methyl groups from lysines in histone tails and other proteins. Cumulating evidence suggests an emerging role for these demethylases in myeloid malignancies, rendering them attractive targets for drug interventions. In this review, we summarize the known functions of Jumonji C (JmjC) domain-containing proteins in myeloid malignancies. We highlight challenges in understanding the context-dependent mechanisms of these proteins and explore potential future pharmacological targeting.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available